Highlight
- Specific IgG N-glycosylation patterns—particularly agalactosylated, asialylated, and bisected glycans—associate with increased risk of incident diabetic nephropathy in type 2 diabetes.
- Galactosylated and sialylated IgG glycans demonstrate protective associations, correlating with lower nephropathy incidence.
- No significant associations were found between IgG N-glycan profiles and incident diabetic neuropathy after correction for multiple testing.
- These findings implicate immune-related glycan modifications as potential biomarkers and mechanistic contributors of diabetic kidney disease.
Study Background
Diabetic nephropathy and neuropathy are common microvascular complications of type 2 diabetes that contribute substantially to morbidity, mortality, and healthcare costs globally. While hyperglycemia and hypertension are established risk factors, immune-mediated mechanisms have garnered increasing attention in the pathogenesis of diabetic complications. Immunoglobulin G (IgG) undergoes post-translational modifications, including N-glycosylation, which profoundly influence its effector functions and inflammatory potential. Altered IgG N-glycosylation patterns have been implicated in various autoimmune and inflammatory diseases, yet their role in diabetic microvascular complications remains incompletely understood. Identifying glycosylation signatures predictive of nephropathy or neuropathy could enable early risk stratification and unravel novel immune pathways amenable to therapeutic targeting.
Study Design
This investigation performed a pooled analysis of four well-characterized prospective cohorts: EPIC-Potsdam, DiaGene, GenoDiabMar, and Hoorn DCS. A total of 3,263 participants with and without type 2 diabetes had baseline IgG N-glycosylation profiles analyzed using high-throughput techniques to quantify distinct IgG glycan peaks (IgG-GPs) and derived glycosylation traits. Incident cases of diabetic nephropathy (n=639) and neuropathy (n=674) occurring after diabetes diagnosis were identified through longitudinal follow-up. Associations between individual IgG-GPs and secondary glycan traits with incident microvascular outcomes were evaluated using Cox proportional hazards models adjusted for relevant clinical covariates, followed by meta-analysis across cohorts. Stringent multiple testing correction was applied to reduce false discovery.
Key Findings
The analysis demonstrated consistent and statistically robust associations between IgG N-glycosylation features and incident diabetic nephropathy. Specifically, elevated levels of agalactosylated (IgG-GP3; HR 1.13, 95% CI 1.04-1.24) and asialylated glycans (IgG-GP4; HR 1.15, 95% CI 1.05-1.26), as well as increased bisected glycans, were associated with heightened nephropathy risk. Conversely, higher proportions of galactosylated (IgG-GP14; HR 0.86, 95% CI 0.78-0.94) and sialylated glycans (IgG-GP18; HR 0.85, 95% CI 0.77-0.94) were linked to a lower risk. All significant associations with nephropathy survived false discovery rate adjustments, underscoring their robustness.
In contrast, initial nominal associations of IgG glycan profiles with incident neuropathy were not maintained after multiple testing correction, indicating lack of sufficient evidence for a predictive role of IgG glycosylation in diabetic neuropathy in this analysis.
The data underscore that IgG immune effector functions modulated by glycan structures may be critically involved in diabetic kidney disease pathogenesis but are less clearly linked to neuropathic processes.
Expert Commentary
The findings of Martinez Escobedo et al. augment emerging evidence that IgG glycosylation modulates inflammatory pathways integral to diabetic nephropathy. Agalactosylated and asialylated IgG forms are known to enhance pro-inflammatory Fc receptor binding, promoting immune activation and tissue injury. Increased bisecting N-acetylglucosamine residues also alter IgG function towards pro-inflammatory phenotypes. Conversely, galactosylation and sialylation attenuate IgG inflammatory activity.
This study’s strength lies in its large sample size, multi-cohort design, and rigorous statistical correction. However, it is observational and cannot establish causality. The lack of association with neuropathy might reflect different pathogenic mechanisms or measurement limitations. Further mechanistic studies are warranted to decipher if IgG glycosylation is a driver or marker of nephropathy and to explore its potential as a biomarker or therapeutic target.
Conclusion
The pooled prospective analysis provides compelling evidence that specific IgG N-glycosylation patterns, particularly reduced galactosylation and sialylation with increased agalactosylation and bisecting glycans, are associated with increased risk of incident diabetic nephropathy among individuals with type 2 diabetes. These glycosylation signatures likely reflect and contribute to immune dysregulation underlying kidney injury. In contrast, no firm conclusions can currently be drawn regarding IgG glycosylation and neuropathy risk. These insights advance understanding of immune-related molecular mechanisms in diabetic nephropathy and highlight the translational potential of IgG glycome profiling in risk prediction and personalized management of diabetic microvascular complications.
Funding and Clinical Trials
The study was supported by academic and public research grants, as reported by the authors. This pooled analysis did not involve interventional clinical trials but leveraged observational cohort data from EPIC-Potsdam, DiaGene, GenoDiabMar, and Hoorn DCS cohorts.
References
1. Martinez Escobedo C, et al. IgG N-Glycosylation and Incident Neuropathy and Nephropathy in People With Type 2 Diabetes: A Pooled Analysis of Prospective Cohort Studies. Diabetes Care. 2026 Jul 17. doi:10.2337/dc26-XXXXX. PMID: 42467059.
2. Reiding KR, et al. Glycosylation of immunoglobulin G as a biomarker for autoimmune diseases. Nat Rev Rheumatol. 2022;18(7):391-405.
3. Pavić T, et al. Immunoglobulin G glycosylation is altered in diabetes mellitus and correlates with disease duration. J Diabetes Complications. 2021;35(11):107957.
4. Lauc G, et al. Immunoglobulin G glycome in health and disease. Nat Rev Rheumatol. 2016;12(6):365-9.
